DIAGNOSTIC VALUE OF TRANS-RECTAL ULTRASOUND GUIDED PROSTATE BIOPSY AFTER PSMA/PET CT IN RESIDUAL/RECURRENT PROSTATE CANCER

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of radiodiagnosis, Faculty of Medicine University of Alexandria.

2 Department of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University

3 Department of Genitourinary surgery, Faculty of Medicine, University of Alexandria

4 Department of Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria

5 Department of Radiodiagnosis and Intervention, Faculty of Medicine, University of Alexandria

Abstract

Prostate cancer represents a significant global health concern, ranking as the second most prevalent male malignancy after lung cancer. In the past two decades, there has been a notable shift in focus toward the diagnostic significance of systematic screening and early detection programs, including serum prostate-specific antigen (PSA) testing has led to a marked reduction in the incidence of advanced-stage progression in prostate cancer (PCa) at the time of diagnosis. The Gleason grading system of PCa assigns a score based on how closely the prostate tissue resembles normal glandular structures under a microscope. As for imaging, while transrectal ultrasound (TRUS)-guided biopsy and MRI have proven useful in prostate cancer, Prostate specific membrane antigen (PSMA) positron emission tomography (PET) Computed tomography (CT), a.k.a PSMA-PET CT is currently on the rise regarding localization of metabolically active prostatic tissue to guide TRUS guided sampling procedures.
Aim:
The aim of this work was to assess the diagnostic value of TRUS guided prostate biopsy compared to PSMA PET/CT in detection of prostate cancer in residual/recurrent disease.

Keywords

ALEXMED ePosters
Volume 6, Issue 4
September 2024
Pages 34-35

Files

Share

How to cite

Statistics